$SEELQ
SEELOS THERAPEUTICS, INC. Stock $seelq

$seelq Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000101749117000091 Filed on August 02, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$0.00	$0.00	$464.0K
YoY Change	-100.0%	-100.0%	0.43%
Cost Of Revenue			$93.00K
YoY Change			-81.73%
Gross Profit			$371.0K
YoY Change			-889.36%
Gross Profit Margin			79.96%
Selling, General & Admin	$1.760M	$1.600M	$2.120M
YoY Change	13.55%	-24.53%	-20.6%
% of Gross Profit			571.43%
Research & Development	$1.960M	$839.0K	$2.503M
YoY Change	1052.94%	-66.48%	-19.44%
% of Gross Profit			674.66%
Depreciation & Amortization	$20.00K	$20.00K	$80.00K
YoY Change	-71.43%	-75.0%	0.0%
% of Gross Profit			21.56%
Operating Expenses	$3.716M	$2.441M	$4.625M
YoY Change	116.05%	-47.22%	-19.93%
Operating Profit	-$3.716M	-$2.441M	-$4.625M
YoY Change	116.05%	-47.22%	-20.57%
Interest Expense	$3.000K	$3.000K	-$258.0K
YoY Change	-101.28%	-101.16%	51.76%
% of Operating Profit
Other Income/Expense, Net	-$293.0K	$719.0K	$1.372M
YoY Change	-336.29%	-47.59%	137.37%
Pretax Income	-$4.010M	-$1.720M	-$3.250M
YoY Change	150.63%	-47.08%	-38.1%
Income Tax			$2.000K
% Of Pretax Income
Net Earnings	-$3.832M	-$1.474M	-$3.338M
YoY Change	196.82%	-55.84%	-36.36%
Net Earnings / Revenue			-719.4%
Basic Earnings Per Share
Diluted Earnings Per Share	-$8.705M	-$3.868M	-$15.90M
COMMON SHARES
Basic Shares Outstanding	12.78M shares	12.77M shares	47.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.460M	$7.820M	$2.720M
YoY Change	50.8%	187.5%	-63.39%
Cash & Equivalents	$8.463M	$7.821M	$2.723M
Short-Term Investments
Other Short-Term Assets	$230.0K	$830.0K	$740.0K
YoY Change	-45.24%	12.16%	-43.51%
Inventory			$778.0K
Prepaid Expenses
Receivables			$687.0K
Other Receivables			$0.00
Total Short-Term Assets	$8.688M	$8.649M	$4.925M
YoY Change	20.07%	75.61%	-49.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$100.0K	$121.0K	$1.163M
YoY Change	-90.83%	-89.6%	-18.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$35.00K	$45.00K	$78.00K
YoY Change	-57.83%	-42.31%	-47.65%
Total Long-Term Assets	$135.0K	$166.0K	$1.241M
YoY Change	-88.5%	-86.62%	-21.16%
TOTAL ASSETS
Total Short-Term Assets	$8.688M	$8.649M	$4.925M
Total Long-Term Assets	$135.0K	$166.0K	$1.241M
Total Assets	$8.823M	$8.815M	$6.166M
YoY Change	4.91%	42.96%	-45.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$260.0K	$140.0K	$1.600M
YoY Change	-81.82%	-91.25%	255.56%
Accrued Expenses	$783.0K	$716.0K	$2.753M
YoY Change	-75.1%	-73.99%	8.73%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$8.070M
YoY Change	-100.0%	-100.0%	777.17%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.814M	$1.844M	$13.27M
YoY Change	-85.61%	-86.1%	166.69%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$54.00K	$60.00K	$131.0K
YoY Change	-32.5%	-54.2%	-46.75%
Total Long-Term Liabilities	$54.00K	$60.00K	$131.0K
YoY Change	-32.5%	-54.2%	-46.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.814M	$1.844M	$13.27M
Total Long-Term Liabilities	$54.00K	$60.00K	$131.0K
Total Liabilities	$2.504M	$2.243M	$15.61M
YoY Change	-84.3%	-85.63%	6.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$313.5M	-$309.7M	-$314.7M
YoY Change	-0.78%	-1.59%	4.38%
Common Stock	$319.9M	$316.3M	$305.3M
YoY Change	3.69%	3.6%	2.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.319M	$6.572M	-$9.441M
YoY Change
Total Liabilities & Shareholders Equity	$8.823M	$8.815M	$6.166M
YoY Change	4.91%	42.96%	-45.86%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$3.832M	-$1.474M	-$3.338M
YoY Change	196.82%	-55.84%	-36.36%
Depreciation, Depletion And Amortization	$20.00K	$20.00K	$80.00K
YoY Change	-71.43%	-75.0%	0.0%
Cash From Operating Activities	-$3.020M	-$2.270M	-$3.230M
YoY Change	251.16%	-29.72%	-62.49%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change		-100.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	$250.0K	$250.0K	$180.0K
YoY Change		38.89%
Cash From Investing Activities	$250.0K	$250.0K	$170.0K
YoY Change		47.06%	-950.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.420M	6.080M	-1.110M
YoY Change	-8.8%	-647.75%	1133.33%
NET CHANGE
Cash From Operating Activities	-3.020M	-2.270M	-3.230M
Cash From Investing Activities	250.0K	250.0K	170.0K
Cash From Financing Activities	3.420M	6.080M	-1.110M
Net Change In Cash	650.0K	4.060M	-4.170M
YoY Change	-77.51%	-197.36%	-52.18%
FREE CASH FLOW
Cash From Operating Activities	-$3.020M	-$2.270M	-$3.230M
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$3.020M	-$2.270M	-$3.220M
YoY Change	251.16%	-29.5%	-62.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	apri	Aggregate Liability Limitation Indemnification Claims AggregateLiabilityLimitationIndemnificationClaims	2000000	USD
CY2017Q2	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	250000	USD
CY2017Q2	apri	Disposal Group Including Discontinued Operation Payments Recognized For Transition Services DisposalGroupIncludingDiscontinuedOperationPaymentsRecognizedForTransitionServices	250000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Carrying Value Of Assets DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodCarryingValueOfAssets	1578000	USD
CY2017Q1	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferred	1186000	USD
	apri	Disposal Group Including Discontinued Operations Disposal During Period Liabilities Transferred After Closing Date DisposalGroupIncludingDiscontinuedOperationsDisposalDuringPeriodLiabilitiesTransferredAfterClosingDate	1100000	USD
CY2017Q2	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000	USD
CY2017Q1	apri	Expected Payments For Transition Services Number Of Quarterly Payments ExpectedPaymentsForTransitionServicesNumberOfQuarterlyPayments	2	payment
CY2017Q1	apri	Expected Payments Received For Delivery Of Product Related Inventory ExpectedPaymentsReceivedForDeliveryOfProductRelatedInventory	709000	USD
CY2017Q1	apri	Expected Payments Received For Delivery Of Product Related Inventory ExpectedPaymentsReceivedForDeliveryOfProductRelatedInventory	700000	USD
CY2017Q1	apri	Expected Payments Received For Transition Services ExpectedPaymentsReceivedForTransitionServices	500000	USD
CY2017Q2	apri	Expected Payments Received For Transition Services ExpectedPaymentsReceivedForTransitionServices	250000	USD
	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	0	USD
	apri	Gain Losseson Extinguishmentof Debt Non Cash Operating GainLossesonExtinguishmentofDebtNonCashOperating	-422000	USD
	apri	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	6119000	USD
	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	0	USD
	apri	Noncash Financing Activities Reclassification Of Warrants To Equity NoncashFinancingActivitiesReclassificationOfWarrantsToEquity	798000	USD
CY2016Q3	apri	Proceeds From Issuance Of Sale Of Equity Net Of Transaction Costs ProceedsFromIssuanceOfSaleOfEquityNetOfTransactionCosts	3200000	USD
CY2016Q1	apri	Proceeds From Issuance Of Sale Of Equity Net Of Transaction Costs ProceedsFromIssuanceOfSaleOfEquityNetOfTransactionCosts	9600000	USD
CY2017Q2	apri	Proceeds From Sale Of Product Related Inventory ProceedsFromSaleOfProductRelatedInventory	700000	USD
CY2017Q2	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2017Q1	apri	Purchase Agreement Maximum Potential Proceeds From Divestiture PurchaseAgreementMaximumPotentialProceedsFromDivestiture	12700000	USD
CY2016Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	142000	USD
CY2017Q2	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	162000	USD
CY2016Q2	apri	Sales Revenue Goods Net Third Party Components SalesRevenueGoodsNetThirdPartyComponents	10000	USD
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	1.56
	apri	Sales Revenue Goods Net Third Party Components SalesRevenueGoodsNetThirdPartyComponents	300000	USD
	apri	Sales Revenue Goods Net Third Party Components SalesRevenueGoodsNetThirdPartyComponents	100000	USD
CY2017Q2	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	6094932	shares
CY2017Q2	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	4.26
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1133
CY2016Q4	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	15.19
CY2017Q2	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	4.26
	apri	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeitedWeightedAverageExercisePrice	52.50
CY2017Q2	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	74100000	USD
CY2014Q3	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	100000000	USD
CY2016Q3	apri	Stock Sale Restriction Period StockSaleRestrictionPeriod	P90D
	apri	Warrant Liability Reclassified To Stockholders Equity WarrantLiabilityReclassifiedToStockholdersEquity	798000	USD
CY2017Q2	apri	Working Capital WorkingCapital	6800000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12783761	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
	dei	Trading Symbol TradingSymbol	APRI
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	686000	USD
CY2017Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	140000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	194000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	56000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	614000	USD
CY2017Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	657000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1236000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	716000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	783000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	395000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	308784000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	316268000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	572000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	739000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1094000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	287000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	572000	USD
CY2016Q4	us-gaap	Assets Assets	4700000	USD
CY2017Q2	us-gaap	Assets Assets	8815000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3634000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	8649000	USD
CY2016Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1370000	USD
CY2017Q2	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	506000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3887000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2723000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2087000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7821000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1164000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5734000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	11750000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-630000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-114000	USD
CY2017Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	6094932	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7733205	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12783761	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7733205	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12783761	shares
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	13000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	135000	USD
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	280000	USD
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	0	USD
CY2016Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	134000	USD
CY2017Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	45000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	145000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	77000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	846000	USD
CY2017Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	339000	USD
CY2017Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	300000	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5100000	USD
CY2017Q1	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	12067000	USD
CY2016Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	-0.01
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	-0.02
CY2017Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	0.02
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic And Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicAndDilutedShare	1.23
CY2016Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	842000	USD
CY2017Q2	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	USD
CY2017Q1	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	12459000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.00
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.69
CY2016Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1637000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4437000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-716000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	292000	USD
CY2016Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-422000	USD
CY2017Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2122000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4328000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1602000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3043000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3253000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5748000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1722000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5141000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.53
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.98
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.15
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.54
CY2016Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-85000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-95000	USD
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	248000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	11740000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	401000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-547000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-513000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-478000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-383000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	43000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-90000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-22000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-14000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	20000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-16000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-218000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	145000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	500000	USD
CY2017Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	100000	USD
CY2016Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-258000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-537000	USD
CY2017Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-92000	USD
	us-gaap	Interest Paid InterestPaid	354000	USD
	us-gaap	Interest Paid InterestPaid	92000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	12216000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	2243000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4700000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8815000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11294000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1844000	USD
CY2016Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	2108000	USD
CY2017Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	331000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9605000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-630000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	11636000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8076000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1051000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	262000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8872000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4851000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-3338000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5843000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-1474000	USD
	us-gaap	Net Income Loss NetIncomeLoss	6599000	USD
	us-gaap	Net Income Loss NetIncomeLoss	6600000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1372000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3684000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	719000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-832000	USD
CY2016Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6650000	USD
CY2017Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	4625000	USD
	us-gaap	Operating Expenses OperatingExpenses	9432000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	2441000	USD
	us-gaap	Operating Expenses OperatingExpenses	4309000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4625000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9432000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2441000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4309000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	177000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	114000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	76000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	60000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2016Q2	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	177000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	322000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2017Q1	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11500000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10900000	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	14.96
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6078000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0136
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	246914	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	4024000	shares
	us-gaap	Stock Issued1 StockIssued1	249000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	2317846	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6094932	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.20
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	415000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	400000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.23
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.31
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7800000	USD
CY2016Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3700000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	164000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	121000	USD
CY2016Q2	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	205000	USD
CY2017Q2	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1526000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7129000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2503000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5104000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	839000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1266000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316308000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-309709000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1094000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	572000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-7516000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	6572000	USD
CY2016Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2017Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	800000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6182000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5843000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11335000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9547000	shares

Files In Submission

Name	View Source	Status
0001017491-17-000091-index-headers.html	Edgar Link	pending
0001017491-17-000091-index.html	Edgar Link	pending
0001017491-17-000091.txt	Edgar Link	pending
0001017491-17-000091-xbrl.zip	Edgar Link	pending
apri-20170630.xml	Edgar Link	completed
apri-20170630.xsd	Edgar Link	pending
apri-20170630_cal.xml	Edgar Link	unprocessable
apri-20170630_def.xml	Edgar Link	unprocessable
apri-20170630_lab.xml	Edgar Link	unprocessable
apri-20170630_pre.xml	Edgar Link	unprocessable
apri6301710q.htm	Edgar Link	pending
apri63017ex310.htm	Edgar Link	pending
apri63017ex311.htm	Edgar Link	pending
apri63017ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEELQ
SEELOS THERAPEUTICS, INC. Stock $seelq

2017 Q3 Form 10-Q Financial Statement

#000101749117000091 Filed on August 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEELQ SEELOS THERAPEUTICS, INC. Stock $seelq

2017 Q3 Form 10-Q Financial Statement

#000101749117000091 Filed on August 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEELQ
SEELOS THERAPEUTICS, INC. Stock $seelq